Daclatasvir Nitroso
Synchemia is a leading Manufacturer in pharmaceutical Nitrosamine compounds. Daclatasvir is used along with another medication (sofosbuvir [Solvadi]) to treat a certain type of chronic hepatitis C (an ongoing viral infection that damages the liver). Daclatasvir is in a class of antiviral medications called hepatitis C virus (HCV) NS5A inhibitors.Daclatasvir Nitroso is a highly toxic organic compound and a suspected human carcinogen. Handle the material carefully with proper safety measures.
Daclatasvir Nitroso CAS NO:NA chemically represented as Methyl ((S)-1-((S)-2-(5-(4'-(2-((S)-1-((methoxycarbonyl)-L-valyl)pyrrolidin-2-yl)-1H-imidazol-5-yl)-[1,1'-biphenyl]-4-yl)-1-nitroso-1H-imidazol-2-yl)pyrrolidin-1-yl)-3-methyl-1-oxobutan-2-yl)carbamate. Synchemia is the leading manufacturing and exporter of Daclatasvir Nitroso . We supply Daclatasvir Nitroso with detailed characterization data compliance with regulatory guidelines.
Make an Enquiry for Abacavir EP Impurity A
Related Products
| CAT No | SRC-N0143348 |
| CAS No | NA |
| Mol.F. | C27H40F2N6O2 |
| Mol.Wt. | 518.7 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143349 |
| CAS No | NA |
| Mol.F. | C27H40F2N6O2 |
| Mol.Wt. | 518.7g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143350 |
| CAS No | NA |
| Mol.F. | C26H26N6O4 |
| Mol.Wt. | 486.5 g/mole |
| INV STATUS | UNDER SYNTHESIS |
| CAT No | SRC-N0143351 |
| CAS No | NA |
| Mol.F. | C26H26N6O4 |
| Mol.Wt. | 486.5 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143352 |
| CAS No | NA |
| Mol.F. | C13H20N2O5 |
| Mol.Wt. | 284.3 g/mole |
| INV STATUS | In Stock |
| CAT No | SRC-N0143353 |
| CAS No | NA |
| Mol.F. | C13H20N2O8S |
| Mol.Wt. | 364.4 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143354 |
| CAS No | NA |
| Mol.F. | C11H14N2O3 |
| Mol.Wt. | 222.2 g/mole |
| INV STATUS | In Stock |
| CAT No | SRC-N0143355 |
| CAS No | NA |
| Mol.F. | C12H16N2O4 |
| Mol.Wt. | 252.3 g/mole |
| INV STATUS | In Stock |
| CAT No | SRC-N0143356 |
| CAS No | NA |
| Mol.F. | C26H37N3O7 |
| Mol.Wt. | 503.60 g/mole |
| INV STATUS | UNDER SYNTHESIS |
| CAT No | SRC-N0143357 |
| CAS No | NA |
| Mol.F. | C13H20N2O8S |
| Mol.Wt. | 364.37 g/mole |
| INV STATUS | UNDER SYNTHESIS |
| CAT No | SRC-N0143358 |
| CAS No | NA |
| Mol.F. | C19H20ClN3O2 |
| Mol.Wt. | 357.84 g/mole |
| INV STATUS | UNDER SYNTHESIS |
| CAT No | SRC-N0143359 |
| CAS No | NA |
| Mol.F. | C17H19N3O3S |
| Mol.Wt. | 345.4 g/mole |
| INV STATUS | UNDER SYNTHESIS |
| CAT No | SRC-N0143360 |
| CAS No | 2114-63-8 |
| Mol.F. | C15H14N2O3 |
| Mol.Wt. | 270.30 g/mole |
| INV STATUS | In Stock |
| CAT No | SRC-N0143361 |
| CAS No | 3979-11-1 |
| Mol.F. | C20H18N2O |
| Mol.Wt. | 302.4 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143362 |
| CAS No | NA |
| Mol.F. | C10H11BrN6O |
| Mol.Wt. | 311.1 g/mole |
| INV STATUS | In Stock |
| CAT No | SRC-N0143363 |
| CAS No | NA |
| Mol.F. | C10H9BrClN5O |
| Mol.Wt. | 330.6 g/mole |
| INV STATUS | UNDER SYNTHESIS |